Shares of Harmony Biosciences Holdings, Inc. (HRMY) have gained 13.4% over the past four weeks to close the last trading session at $32.66, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $43.38 indicates a potential upside of 32.8%.The average comprises eight short-term price targets ranging from a low of $28 to a high of $56, with a standard deviation of $10.10. While the lowe ...